PROGRAMMA PRELIMINARE
XXXIX CONGRESSO NAZIONALE AISP
(aggiornato al 30 luglio 2015)
PRESIDENTE DEL CONGRESSO
Alessandro Zerbi
COMITATO SCIENTIFICO
Giovanni Boz
Gabriele Capurso
Stefano Crippa
Paola Fogar
Armando Gabrielli
Elisa Giovannetti
COMITATO ORGANIZZATORE LOCALE
Paola Allavena
Silvia Carrara
Francesca Gavazzi
Luigi Laghi
Alberto Malesci
PROGRAMMA SCIENTIFICO
XXXIX CONGRESSO NAZIONALE AISP (Associazione Italiana per lo Studio del Pancreas)
VENERDÌ 23 OTTOBRE 2015
Sala Blu 1
Ore 08.30-09.00
INAUGURAZIONE
F. Corcione (NA), G. Delle Fave (RM), M. Montorsi (MI), A. Zerbi (MI)
Ore 09.00-09.30
STUDI AISP
Moderatori: G. Capurso (RM), A. Zerbi (MI)
Linee Guida AISP Pancreatite Acuta
R. Pezzilli (BO)
Trial chemioterapia neoadiuvante
G. Balzano (MI)
Stenting in malattie del pancreas
M. Mutignani (MI)
Trial fluidi nella pancreatite acuta
G. Capurso (RM)
Registro resezioni laparoscopiche del pancreas SICE-AISP
M. Morino (TO)
Discussione
Ore 09.30-11.00
LA PALLIAZIONE DELLE NEOPLASIE PANCREATICHE
Moderatori: G. Boz (PN), A. Repici (MI)
Endoscopia: stent via biliare e duodeno
M. Traina (PA)
Endoscopia: stents EUS guidati
A. Larghi (RM)
Chirurgia
R. Casadei (BO)
La qualità di vita, il dolore, la nutrizione
A. Andriulli (FG)
Chemioterapia
C. Carnaghi (MI)
Radioterapia
A. G. Morganti (BO)
Discussione
Ore 11.00-11.20 Break
Ore 11.20-13.00
TAVOLA ROTONDA
RICERCA TRASLAZIONALE E ADENOCARCINOMA DEL PANCREAS
Moderatori: A. Malesci (MI), A. Scarpa (VR)
La fibrosi: ostacolo o possibile target?
F. Novelli (TO)
Risposta immunitaria
P. Allavena (MI)
Opportunità dai modelli di colture primarie
N. Funel (PI)
Infiammazione e markers diagnostici
D. Basso (PD)
Quale spazio per la Next-Generation Sequencing
L. Laghi (MI)
Perché le target therapy hanno fallito?
E. Raymond (SVIZZERA)
Medicina traslazionale in AISP: scenari possibili, una piattaforma comune?
L. Piemonti (MI)
Discussione
Ore 13.00-13.30
SIMPOSIO CONGIUNTO AISP-SID
IL CROSS-TALK ACINO-INSULA
Moderatori: G. Delle Fave (RM), F. Marotta (MI)
Il punto di vista del diabetologo
P. Marchetti (PI)
Il punto di vista del gastroenterologo
R. Pezzilli (BO)
Discussione
Ore 13.30-14.30 Pausa pranzo & Poster round
Moderatori: G. Capurso (RM), S. Crippa (MI)
Ore 14.30-15.30
COMUNICAZIONI ORALI
Scienza di base
Moderatori: P. Fogar (PD), L. Gianotti (MB)
Pacetti
Moz
Picariello
Carbone
Passacantilli
Funel
Tacelli
Tavano
Association of AKT1 and SELP Polymorphisms with Cachexia and Survival of Patients
with Pancreatic Cancer
Blood expression of Matrix Metalloproteinases 8 and 9 and of their inducers S100A8
and S100A9 supports diagnosis and prognosis of PDAC-associated Diabetes Mellitus
Pancreatic Stellate Cells promote pluripotency in pancreatic cancer cells
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in vivo
acquired resistance to anti VEGF treatment.
ZEB1 Regulates DNA Damage Response During Gemcitabine Treatment in PDACs Cells
TGF-β/EGFR AUTOCRINE CROSS-TALK AFFECTS EMT PROCESS AND MIGRATION IN 3D
TISSUE-ENGENEERED MODEL OF PANCREATIC DUCTAL ADENOCARCINOMA
Epithelial-to-Mesenchymal Transition (EMT) and Pancreatic Cancer progression
Digital quantification of microRNA in plasma for early diagnosis of pancreatic cancer
Ore 15.30-16.30
UTILIZZO DI RMN (risonanza magnetica nucleare) ED EUS (ecoendoscopia) IN SITUAZIONI CLINICHE
PARTICOLARI
Moderatori: L. Calculli (BO), M. Falconi (MI)
Screening cancro familiare: stato dell’arte
J.W. Poley (PAESI BASSI)
Screening cancro familiare: la situazione in Italia
M. Del Chiaro (SVEZIA)
Follow-up IPMN: perché con EUS
S. Carrara (MI)
Follow-up IPMN: perché con MRI
R. Salvia (VR)
Come validare le linee guida italiane: lo studio PANCY
E. Buscarini (CR)
Discussione
Ore 16.30-17.00 Break
Ore 17.00-18.00
COMUNICAZIONI ORALI
Malattie infiammatorie del pancreas
Moderatori: G.M. Cavestro (MI), S. Crippa (MI)
Marchegiani
The Risk of Malignancy in 1,712 Patients Resected for Intraductal Papillary Mucinous
Neoplasms (IPMN) of the Pancreas: A Report from the Pancreatic Surgical Consortium
Crippa
Low Progression Of Intraductal Papillary Mucinous Neoplasms With Worrisome
Features And High-Risk Stigmata Undergoing Non-Operative Management: A MidTerm Follow-Up Analysis
Value of Magnetic Resonance Diffusion-Weighted Imaging in the Evaluation of
Pancreatic Neuroendocrine Neoplasms
Prevalence of Chronic Pancreatitis: Preliminary Results of a Primary Care Physicians
based Population-Study
Bile Duct Involvement in Autoimmune Pancreatitis: Clinical Features and Prognostic
Aspects in 92 Patients
Endoscopic Ultrasonography May Select Subjects Having Chronic Asymptomatic
Pancreatic Hyperenzymemia Who Require A More Strict Follow-Up
Comparison of Capillary vs Aspiration Technique in Endoscopic Ultrasound-guided Fine
Needle Aspiration (EUS-FNA): a Preliminary Report
A Multimodal, One-Session Endoscopic Approach for Management of Patients with
Advanced Pancreatic Cancer.
De Robertis
Capurso
Campagnola
Antonini
Dabizzi
Manta
Ore 18.00-18.30
ASSEMBLEA
SABATO 24 OTTOBRE 2015
Sala Blu 1
Ore 08.30-09.30
LA PANCREASECTOMIA TOTALE
Moderatori: C. Bassi (VR), G. Uomo (NA)
Indicazioni e aspetti chirurgici
P. Di Sebastiano (CH)
La gestione dell’insufficienza esocrina totale
M. Piciucchi (RM)
La gestione del diabete
A. Secchi (MI)
Discussione
Ore 9.30-10.30
COMUNICAZIONI ORALI
Carcinoma del pancreas
Moderatori: G. Balzano (MI), S. Massironi (MI)
Archibugi
Palini
Cosi
Castino
Frampton
Giordano
Comito
D'Onofrio
Aspirin, Statins, and Their Combined Use Do Not Reduce The Risk of Pancreatic Cancer
Early detection of pancreatic cancer in high risk population: experience of a medical –
nursing managed screening ambulatory.
Familial Pancreatic Cancer In A Population Of Hospitalized Patients
Dual Prognostic Significance of Tumor Associated Macrophages in Human Pancreatic
Adenocarcinoma Treated or not with Chemotherapy
THE MICRORNA PROCESSING ENDORIBONUCLEASE DICER HAS ALTERED EXPRESSION
IN PANCREATIC DUCTAL ADENOCARCINOMA AND PROGNOSTIC IMPLICATIONS
Nab-Paclitaxel (Nab-P) and Gemcitabine (G) as First Line Chemotherapy (CT) in
Advanced Pancreatic Cancer (APDAC) Patients (pts): an Italian “Real Life” Study
What role for stereotactic body radiotherapy (SBRT) in the treatment of pancreatic
cancer? Clinical results of a phase II study
Percutaneous Ultrasound-Guided Radiofrequency Ablation (RFA) of Pancreatic Ductal
Adenocarcinoma
Ore 10.30-11.00 Break
Ore 11.00-11.30
AISP INCONTRA EPC: PANCREAS 2000
Moderatori: G. Capurso (RM), M. Del Chiaro (SVEZIA)
Storia del progetto
M. Del Chiaro (SVEZIA)
Prospettive attuali e future
G. Capurso (RM)
Esperienze vissute e discussione
Ore 11.30-12.00
PANCREATITE DA IPERTRIGLICERIDEMIA
Moderatori: E. Giovannetti (PI), P. A. Testoni (MI)
Incidenza, problematiche cliniche ed approccio terapeutico
L. Frulloni (VR)
Nuove possibilità terapeutiche: terapia genica nei pazienti portatori di mutazioni della lipoproteinlipasi
C. Zambon (PD)
Discussione
Ore 12.00-13.00
COMUNICAZIONI ORALI
Chirurgia del pancreas
Moderatori: P. De Rai (MI), A. Gabbrielli (VR)
Nappo
Milanetto
Andrianello
Sandini
Giardino
Uccelli
Bissolati
Taffurelli
Lymphadenectomy for periampullary cancer: prognostic role of different metastatic
nodal stations and of the number of metastatic lymph nodes
Central Pancreatectomy: Experience with 129 consecutive Patients Treated in Two
European Pancreatic Centers
Pancreaticojejunostomy After Pancreaticoduodenectomy: Suture Material and
Incidence of Post-Operative Pancreatic Fistula
Preoperative Computed Tomography to Predict and Stratify the Risk of Severe
Pancreatic Fistula
after Pancreatoduodenectomy
C-Reactive Protein and Procalcitonin as Predictors of Postoperative Complications after
Pancreaticoduodenectomy: a Prospective Study
Readmission After Pancreaticoduodenectomy In An Italian Setting
Spleen-Preserving Pancreatic Resections with Preservation of Splenic Vessels: a
Cautionary Note on the Risk of Vascular Complications
Laparoscopic distal pancreatectomy in benign or premalignant pancreatic lesions: is it
really more cost-effective than open approach?
Ore 13.00-13.30
PREMIAZIONE E CHIUSURA CONGRESSO